UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

Oncogene, 2016-06, Vol.35 (24), p.3209-3216

2016

Volltextzugriff (PDF)

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S79-S79

2016

Volltextzugriff (PDF)

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

Annals of oncology, 2016-10, Vol.27, p.vi577-vi577

2016

Volltextzugriff (PDF)

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

Annals of oncology, 2019-04, Vol.30, p.ii31-ii32

2019

Volltextzugriff (PDF)

A Gene Expression Platform to Predict Benefit From Adjuvant External Beam Radiation in Resected Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S76-S77

2014

Volltextzugriff (PDF)

Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors Among Patients with Lung Cancer

International journal of radiation oncology, biology, physics, 2017-05, Vol.98 (1), p.224-224

2017

Volltextzugriff (PDF)

Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials

Annals of oncology, 2018-10, Vol.29, p.viii731-viii731

2018

Volltextzugriff (PDF)

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-06, Vol.376 (25), p.2415-2426

2017

Volltextzugriff (PDF)

Abstract No. 139 ▪ FEATURED ABSTRACT Transarterial Chemoperfusion Treatment of Unresectable Pleural Mesothelioma: A Phase 2 Prospective Study

Journal of vascular and interventional radiology, 2023-03, Vol.34 (3), p.S65-S65

2023

Volltextzugriff (PDF)

Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases

International journal of radiation oncology, biology, physics, 2022-02, Vol.112 (2), p.e14-e14

2022

Volltextzugriff (PDF)

P1.04-09 Predictive Clinical and Molecular Features of Long-Term Survivors Receiving Immune Checkpoint Inhibitors for Stage 4 Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S441-S442

2019

Volltextzugriff (PDF)

Abstract No. 1 ▪ ABSTRACT OF THE YEAR Transarterial chemoperfusion treatment of unresectable pleural mesothelioma: interim results of a phase 2 prospective study

Journal of vascular and interventional radiology, 2020-03, Vol.31 (3), p.S4-S4

2020

Volltextzugriff (PDF)

MA13.02 Phase II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Recurrent Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S924-S925

2021

Volltextzugriff (PDF)

Prospective Phase I/II Study of Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.S3-S4

2021

Volltextzugriff (PDF)

Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.e567-e567

2021

Volltextzugriff (PDF)

MA05.06 Feasibility and Safety of Transarterial Chemoperfusion for Advanced Pleural Mesothelioma: Interim Results of a Phase 2 Study

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S266-S267

2019

Volltextzugriff (PDF)

Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma

Journal of immunotherapy (1997), 2013-10, Vol.36 (8), p.442-450

2013

Volltextzugriff (PDF)

A Prospective Single Arm Phase I/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.S36-S36

2019

Volltextzugriff (PDF)

84OPhase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

Annals of oncology, 2019-04, Vol.30 (Supplement_2)

2019

Volltextzugriff (PDF)

MA 12.03 Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1848-S1848

2017

Volltextzugriff (PDF)

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, International Study of Medi4736 in Patients with Locally Advanced, Unresectable, Stage 3 Nsclc Who Have not Progressed Following Platinum-Based, Concurrent Chemoradiation Therapy (PACIFIC)

Annals of oncology, 2015-04, Vol.26, p.i24

2015

Volltextzugriff (PDF)

OA05.03 Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S330-S331

2018

Volltextzugriff (PDF)

Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2017-09, Vol.28, p.v461

2017

Volltextzugriff (PDF)

P1.04-32 Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S538-S538

2018

Volltextzugriff (PDF)

P2.09-17 A Call to Action: Rapid Collection of Post-Mortem Lung Cancer Tissue in the Community to Enable Lung Cancer Research

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S767-S768

2018

Volltextzugriff (PDF)

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(82)

Sprache

Englisch
(82)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

A Gene Expression Platform to Predict Benefit From Adjuvant External Beam Radiation in Resected Non-Small Cell Lung Cancer

Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors Among Patients with Lung Cancer

Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Abstract No. 139 ▪ FEATURED ABSTRACT Transarterial Chemoperfusion Treatment of Unresectable Pleural Mesothelioma: A Phase 2 Prospective Study

Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases

P1.04-09 Predictive Clinical and Molecular Features of Long-Term Survivors Receiving Immune Checkpoint Inhibitors for Stage 4 Non-Small Cell Lung Cancer

Abstract No. 1 ▪ ABSTRACT OF THE YEAR Transarterial chemoperfusion treatment of unresectable pleural mesothelioma: interim results of a phase 2 prospective study

MA13.02 Phase II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Recurrent Non-Small Cell Lung Cancer

Prospective Phase I/II Study of Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC

Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone

MA05.06 Feasibility and Safety of Transarterial Chemoperfusion for Advanced Pleural Mesothelioma: Interim Results of a Phase 2 Study

Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma

A Prospective Single Arm Phase I/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer

84OPhase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

MA 12.03 Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, International Study of Medi4736 in Patients with Locally Advanced, Unresectable, Stage 3 Nsclc Who Have not Progressed Following Platinum-Based, Concurrent Chemoradiation Therapy (PACIFIC)

OA05.03 Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC

Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)

P1.04-32 Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC

P2.09-17 A Call to Action: Rapid Collection of Post-Mortem Lung Cancer Tissue in the Community to Enable Lung Cancer Research

Suchergebnisse filtern